|
|
| |
Key People
at Guided Therapeutics |
| |
Mark
L. Faupel, Ph.D., President, Chief Executive Officer and Director.
 Dr.
Faupel has more than 25 years of experience as a senior
executive developing non-invasive alternatives to
surgical biopsies and blood tests, especially in the
area of cancer screening and diagnostics. Prior to
coming to SpectRx in 1998 as Vice President of Business
Development and then co-founding Guided Therapeutics,
Dr. Faupel was a senior executive and co-founder of
Biofield Corp. In 2007, he became President and CEO of
Guided Therapeutics.
He
is the inventor on 20 U.S. patents and author of
numerous scientific publications and presentations,
appearing in such peer-reviewed journals as The Lancet,
Cancer, The European Journal of Radiology and Diabetes
Technology & Therapeutics. He has served as a member of
the European School of Oncology Task Force and on
National Institutes of Health review panels. Dr. Faupel
earned his Ph.D. in neuroanatomy and physiology from the
University of Georgia.
|
| |
Richard
L. Fowler, Sr. Vice-president, Engineering.
 Mr. Fowler is responsible for identifying new
technical and business opportunities for Guided Therapeutics. These opportunities include
new technologies, product lines or business acquisitions that are strategic to
the Company's business. Mr. Fowler was formerly VP of Engineering at Guided
Therapeutics
where he oversaw the successful development of the BiliChek® Non-invasive Bilirubin Analyzer.
Mr. Fowler has more than 20 years experience in developing and bringing to
market electro-optical devices. Prior to joining Guided Therapeutics, Mr. Fowler was
President of Laser Atlanta Optics, Inc. where he developed and launched a new,
low-cost laser range finder. He has also held management positions with GEC
Avionics, Inc. and General Dynamics. Mr. Fowler holds a degree in Electrical
Engineering from the University of Texas.
|
| |
Shabbir
Bambot, Ph.D. Vice President, Research and Development.
 Dr. Bambot is a co-founder of Guided
Therapeutics. He has 20 years of experience in
developing medical diagnostic products and is
co-inventor of the technology behind the company’s
cancer diagnostic products. At present he manages the
development of the company’s esophageal cancer
surveillance product in partnership with Konica Minolta
Opto, Japan.
He
has been instrumental in the successful launch of two
point-of-care medical diagnostic products, the AVL/Roche
OPTI 2® blood chemistry analyzer and the Guided
Therapeutics BiliChek® Non-invasive Bilirubin Analyzer.
Dr. Bambot has 8 patents, several publications and
presentations in the areas of clinical monitoring and
diagnostics and is the recipient of multiple NIH SBIR
grants totaling in excess of $6.0 million for developing
non-invasive diagnostic devices. He has experience with
regulatory strategy and FDA 510K & PMA applications,
quality systems compliance, clinical studies and
regulations for conducting research on human subjects. |
|
